The 5,500-square-meter building will produce more reagents for developers of vaccines and therapy products, including COVID-19 vaccines, the company has said in a press release.
"The expansion project testifies to the potential of our country – from advanced research and training of young talents to our ability to implement projects together with Lithuanian partners in a very short time," said Thermo Fisher Scientific Baltics CEO Algimantas Markauskas.
The company began producing reagents for COVID-19 testing last spring.
The new unit has created almost 150 new jobs. The company employs a total of 1,300 people.
It is prohibited to copy and republish the text of this publication without a written permission from UAB „BNS“.
BNS
Comment
Show discussion